Mutual of America Capital Management LLC Trims Stock Holdings in Krystal Biotech, Inc. (NASDAQ:KRYS)

Mutual of America Capital Management LLC trimmed its holdings in Krystal Biotech, Inc. (NASDAQ:KRYS) by 3.1% during the 4th quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 36,388 shares of the company’s stock after selling 1,151 shares during the quarter. Mutual of America Capital Management LLC’s holdings in Krystal Biotech were worth $4,514,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors have also recently modified their holdings of the business. Allspring Global Investments Holdings LLC raised its holdings in shares of Krystal Biotech by 8.4% in the fourth quarter. Allspring Global Investments Holdings LLC now owns 59,324 shares of the company’s stock worth $7,360,000 after buying an additional 4,588 shares during the period. Mirae Asset Global Investments Co. Ltd. raised its holdings in shares of Krystal Biotech by 7.7% in the fourth quarter. Mirae Asset Global Investments Co. Ltd. now owns 13,484 shares of the company’s stock worth $1,673,000 after buying an additional 969 shares during the period. Prime Capital Investment Advisors LLC purchased a new stake in shares of Krystal Biotech in the fourth quarter worth approximately $310,000. China Universal Asset Management Co. Ltd. raised its holdings in shares of Krystal Biotech by 353.9% in the fourth quarter. China Universal Asset Management Co. Ltd. now owns 3,259 shares of the company’s stock worth $404,000 after buying an additional 2,541 shares during the period. Finally, Vanguard Group Inc. raised its holdings in shares of Krystal Biotech by 40.7% in the third quarter. Vanguard Group Inc. now owns 2,400,142 shares of the company’s stock worth $278,416,000 after buying an additional 693,852 shares during the period. 86.29% of the stock is currently owned by hedge funds and other institutional investors.

Insider Transactions at Krystal Biotech

In other news, insider Suma Krishnan sold 25,000 shares of the firm’s stock in a transaction on Monday, March 11th. The stock was sold at an average price of $170.96, for a total value of $4,274,000.00. Following the completion of the sale, the insider now owns 1,550,882 shares of the company’s stock, valued at approximately $265,138,786.72. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. In other news, CAO Kathryn Romano sold 8,087 shares of the firm’s stock in a transaction on Monday, February 26th. The stock was sold at an average price of $136.91, for a total value of $1,107,191.17. Following the completion of the sale, the chief accounting officer now owns 12,556 shares of the company’s stock, valued at approximately $1,719,041.96. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, insider Suma Krishnan sold 25,000 shares of Krystal Biotech stock in a transaction dated Monday, March 11th. The stock was sold at an average price of $170.96, for a total value of $4,274,000.00. Following the sale, the insider now directly owns 1,550,882 shares of the company’s stock, valued at approximately $265,138,786.72. The disclosure for this sale can be found here. Insiders sold 40,587 shares of company stock valued at $6,535,591 in the last quarter. 17.00% of the stock is currently owned by corporate insiders.

Krystal Biotech Trading Down 2.2 %

Shares of NASDAQ KRYS opened at $169.75 on Tuesday. The stock has a market capitalization of $4.84 billion, a PE ratio of 2,121.88 and a beta of 0.85. The stock’s fifty day simple moving average is $155.46 and its two-hundred day simple moving average is $128.83. Krystal Biotech, Inc. has a 12-month low of $82.09 and a 12-month high of $189.97.

Krystal Biotech (NASDAQ:KRYS) last announced its earnings results on Monday, February 26th. The company reported $0.30 earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.52) by $0.82. The company had revenue of $42.14 million for the quarter, compared to the consensus estimate of $27.43 million. During the same period last year, the business posted ($1.25) EPS. On average, equities analysts predict that Krystal Biotech, Inc. will post 1.61 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

Several research firms have commented on KRYS. Citigroup raised their price objective on Krystal Biotech from $160.00 to $195.00 and gave the stock a “buy” rating in a report on Tuesday, February 27th. Guggenheim raised their price objective on Krystal Biotech from $130.00 to $175.00 and gave the stock a “buy” rating in a report on Tuesday, February 27th. Finally, William Blair restated an “outperform” rating on shares of Krystal Biotech in a report on Tuesday, February 27th. Nine research analysts have rated the stock with a buy rating, According to data from MarketBeat, the company has an average rating of “Buy” and a consensus target price of $157.67.

Krystal Biotech Company Profile

Krystal Biotech, Inc, a commercial-stage biotechnology company, discovers, develops, and commercializes genetic medicines for patients with rare diseases in the United States. It commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB).